Search research articles
Contact Us
Filters
Showing results (321-330 of 335) with videos related to
Page
of 34
Sort By:
Science Advances
|
February 11, 2022
Intestinal butyrate-metabolizing species contribute to autoantibody production and bone erosion in rheumatoid arthritis
Jing He, Yanan Chu, Jing Li, et al.
Signal Transduction and Targeted Therapy
|
March 7, 2022
Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial
Xiaoying Zhang, Miao Miao, Ruijun Zhang, et al.
Cell Reports. Medicine
|
July 2, 2025
Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging
Zihan Zhang, Bin Ma, Buyao Li, et al.
Science Advances
|
May 22, 2026
P2X7R of synovial fibroblasts is a potential therapeutic target associated with refractory rheumatoid arthritis
Peishi Rao, Shanzhao Jin, Shibai Xiao, et al.
JCI Insight
|
August 20, 2024
The aberrant tonsillar microbiota modulates autoimmune responses in rheumatoid arthritis
Jing Li, Shenghui Li, Jiayang Jin, et al.
Immunology
|
September 3, 2022
Dynamics of T follicular helper cells in patients with rheumatic diseases and subsequent antibody responses in a three-dose immunization regimen of CoronaVac
Xingyu Zhou, Yifan Wang, Bo Huang, et al.
Science (New York, N.Y.)
|
October 6, 2018
An autoimmune disease variant of IgG1 modulates B cell activation and differentiation
Xiangjun Chen, Xiaolin Sun, Wei Yang, et al.
Nature Communications
|
January 7, 2026
Efficacy and safety of low-dose interleukin 2 for Behçet's syndrome: a randomized, placebo-controlled, double-blind, phase 2 clinical trial
Tian Liu, Wenyan Zhou, Yan Zhu, et al.
Annals of the Rheumatic Diseases
|
September 21, 2019
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
Jing He, Ruijun Zhang, Miao Shao, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
August 28, 2022
Tonsillar Microbiome-Derived Lantibiotics Induce Structural Changes of IL-6 and IL-21 Receptors and Modulate Host Immunity
Jing Li, Jiayang Jin, Shenghui Li, et al.
Page
of 34
Search research articles
Search
Showing results (321-330 of 335) with videos related to
Sort By:
Page
of 34
Science Advances
|
February 11, 2022
Intestinal butyrate-metabolizing species contribute to autoantibody production and bone erosion in rheumatoid arthritis
Jing He, Yanan Chu, Jing Li, et al.
Signal Transduction and Targeted Therapy
|
March 7, 2022
Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial
Xiaoying Zhang, Miao Miao, Ruijun Zhang, et al.
Cell Reports. Medicine
|
July 2, 2025
Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging
Zihan Zhang, Bin Ma, Buyao Li, et al.
Science Advances
|
May 22, 2026
P2X7R of synovial fibroblasts is a potential therapeutic target associated with refractory rheumatoid arthritis
Peishi Rao, Shanzhao Jin, Shibai Xiao, et al.
JCI Insight
|
August 20, 2024
The aberrant tonsillar microbiota modulates autoimmune responses in rheumatoid arthritis
Jing Li, Shenghui Li, Jiayang Jin, et al.
Immunology
|
September 3, 2022
Dynamics of T follicular helper cells in patients with rheumatic diseases and subsequent antibody responses in a three-dose immunization regimen of CoronaVac
Xingyu Zhou, Yifan Wang, Bo Huang, et al.
Science (New York, N.Y.)
|
October 6, 2018
An autoimmune disease variant of IgG1 modulates B cell activation and differentiation
Xiangjun Chen, Xiaolin Sun, Wei Yang, et al.
Nature Communications
|
January 7, 2026
Efficacy and safety of low-dose interleukin 2 for Behçet's syndrome: a randomized, placebo-controlled, double-blind, phase 2 clinical trial
Tian Liu, Wenyan Zhou, Yan Zhu, et al.
Annals of the Rheumatic Diseases
|
September 21, 2019
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
Jing He, Ruijun Zhang, Miao Shao, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
August 28, 2022
Tonsillar Microbiome-Derived Lantibiotics Induce Structural Changes of IL-6 and IL-21 Receptors and Modulate Host Immunity
Jing Li, Jiayang Jin, Shenghui Li, et al.
Page
of 34